Thiopurines, such as mercaptopurine (MP), are immunosuppressive agents, used in the treatment of acute lymphoblastic leukemia (ALL) and inflammatory bowel disease (IBD). Thiopurine methyltransferase (TPMT) is an enzyme involved in thiopurines metabolism with activity modulated by Protein Kinase C and Casein Kinase Substrate in Neurons 2 (PACSIN2). Moreover, the PACSIN2 Single Nucleotide Polymorphism (SNP) rs2413739 eQTL is associated with MP-related gastrointestinal toxicity in children with ALL and with azathioprine efficacy in IBD pediatric patients. PACSIN2 is involved in vesicular trafficking and interacts with Rac1, a GTPase regulating cytoskeletal organization, and a molecular target of thiopurines. PACSIN2 may affect the release and content of extracellular vesicles (EVs), which mediate cell communication and whose cargo modifies phenotypes of target cells. This study evaluates mechanisms associating PACSIN2 polymorphism with interindividual variability in efficacy of thiopurines, by considering effects of PACSIN2 modulation on MP cytotoxicity, biomechanical properties and the release and content of EVs. Effects of stable PACSIN2 knock-down (KD) were evaluated in intestinal LS180 cells. MTT cytotoxicity assay was used to verify MP-sensitivity in both cell lines, then biomechanical properties, Rac1 protein expression and its GTPase activity were investigated respectively by atomic force microscopy (AFM), Western Blot assay (WB) and G-LISA assay in untreated cells and after MP exposure for 24, 48 and 72 hours at IC20, IC50 and IC80. EVs, released by LS180 MOCK and KD were isolated by ultracentrifuge and characterized by nanoparticle tracking analysis (NTA), scanning electron microscopy (SEM), AFM and WB. Intracellular and EVs miRNA-sequencing was performed by Illumina Hi-seq 2000. EVs may alter drug cytotoxicity, therefore LS180 MOCK and KD cells were co-treated with MP and EVs. Statistical analysis was performed using t-test and ANOVA. LS180 PACSIN2 KD were more sensitive to MP than control cells (MOCK) (IC50 LS180 MOCK 3.23 µM; IC50 LS180 KD 2.18 µM). Rac1 protein concentration was higher in LS180 KD cells compared to LS180 MOCK (fold change KD vs MOCK 20.6; p = 0.0009). MP caused a concentration- and dose-dependent reduction of Rac1 protein expression, GTPase activity and stiffness in both cell lines. No differences were observed in terms of release of EVs between MOCK and KD cells (MOCK, 9.39 * 1010 ± 6.50 * 109 particles/mL vs KD 9.91 * 1010± 3.41 * 1010; p = 0.8). PACSIN2 KD altered intracellular and EVs expression of 6 and 23 miRNAs respectively. EV-KD reduced MP cytotoxicity (about 10%): LS180 KD cell lines became more resistent than LS180 MOCK cell line. Moreover, EV-KD reduced Rac1 protein expression in LS180 KD cells (MOCK CTRL: 14.0 ± 5.9; EVs-MOCK: 22.6 ± 5.0; EVs-KD: 51.72 ± 19.8; KD CTRL: 138.9 ± 67.1; EVs-MOCK: 103.4 ± 19.0; EVs-KD: 63.3 ± 23.9; p < 0.001). In conclusion, PACSIN2 KD increases MP cytotoxicity by modifying EVs miRNAs, which could modulate Rac1 protein expression. The association of candidate miRNAs with interindividual variability in the efficacy of thiopurines will be clinically validated in EVs isolated from plasma of IBD pediatric patients treated with thiopurines.

Le tiopurine, come la mercaptopurina (MP), sono farmaci immunosoppressori, utilizzati nel trattamento della leucemia linfoblastica acuta (LLA) e delle malattie infiammatorie intestinali croniche (MICI). La Tiopurina S-metiltransferasi (TPMT) è un enzima coinvolto nel metabolismo delle tiopurine, la cui attività è modulata dalla Protein Kinase C e dalla Casein Kinase Substrate in Neurons 2 (PACSIN2). Inoltre, il polimorfismo a singolo nucleotide (SNP) rs2413739 di PACSIN2 è associato alla tossicità gastrointestinale da MP nei bambini affetti da LLA e all'efficacia dell'azatioprina nei pazienti pediatrici affetti da MICI. PACSIN2 è coinvolto nel traffico vescicolare e interagisce con Rac1, una proteina ad attività GTPasica che regola l'organizzazione citoscheletrica e che rappresenta un bersaglio molecolare per la classe dei farmaci tiopurinici. PACSIN2 può influenzare il rilascio e il contenuto delle vescicole extracellulari (VE), che mediano la comunicazione cellulare e il cui carico modifica i fenotipi delle cellule bersaglio. Questo studio valuta i meccanismi che associano il polimorfismo di PACSIN2 alla variabilità interindividuale dell'efficacia delle tiopurine, considerando gli effetti della modulazione di PACSIN2 sulla citotossicità di MP, le proprietà biomeccaniche, il rilascio e il contenuto di VE. Gli effetti del knock-down (KD) di PACSIN2 sono stati valutati in cellule intestinali LS180. Il saggio di citotossicità MTT è stato utilizzato per verificare la sensibilità al MP in entrambe le linee cellulari, quindi le proprietà biomeccaniche, l'espressione della proteina Rac1 e la sua attività GTPasica sono state studiate rispettivamente con la microscopia a forza atomica (AFM), il saggio di Western Blot (WB) e il saggio G-LISA in cellule non trattate e dopo esposizione al MP per 24, 48 e 72 ore a IC20, IC50 e IC80. Le VE, rilasciate dalle linee cellulari LS180 MOCK e LS180 KD per PACSIN2, sono state isolate mediante ultracentrifuga e caratterizzate mediante analisi di tracciamento delle nanoparticelle (NTA), microscopia elettronica a scansione (SEM), AFM e WB. Il sequenziamento dei miRNA intracellulari e delle VE è stato eseguito con Illumina Hi-seq 2000. Le VE possono alterare la citotossicità dei farmaci, pertanto le cellule LS180 MOCK e LS180 KD per PACSIN2 sono state co-trattate con MP e VE. L'analisi statistica è stata eseguita mediante t-test e ANOVA.   Le LS180 KD per PACSIN2 erano più sensibili al MP rispetto alle cellule di controllo (MOCK) (IC50 LS180 MOCK: 3,23 µM; IC50 LS180 KD: 2,18 µM). La concentrazione di proteina Rac1 era maggiore nelle cellule LS180 KD per PACSIN2 rispetto alle LS180 MOCK (fold change KD vs MOCK 20,6; p = 0,0009). MP ha causato una riduzione concentrazione e dose-dipendente dell'espressione della proteina Rac1, dell'attività della GTPasi e della rigidità in entrambe le linee cellulari. Non sono state osservate differenze in termini di rilascio di VE tra le cellule intestinali MOCK e KD per PACSIN2 (MOCK: 9,39 * 1010 ± 6,50 * 109 particelle/mL vs KD: 9,91 * 1010 ± 3,41 * 1010; p = 0,8). Il knock-down di PACSIN2 ha alterato l'espressione intracellulare e delle VE rispettivamente di 6 e 23 miRNA. Le VE rilasciate dalla linea cellulare LS180 KD per PACSIN2 (EV-KD) ha ridotto la citotossicità a MP (circa il 10%) e l'espressione della proteina Rac1 nelle cellule LS180 KD per PACSIN2 (MOCK CTRL: 14,0 ± 5,9; VE-MOCK: 22,6 ± 5,0; VE-KD: 51,72 ± 19,8; KD CTRL: 138,9 ± 67,1; VE-MOCK: 103,4 ± 19,0; VE-KD: 63,3 ± 23,9; p < 0,001). In conclusione, il knock-down di PACSIN2 aumenta la citotossicità del MP modificando i miRNA delle VE, che potrebbero modulare l'espressione della proteina Rac1. L'associazione dei miRNA candidati con la variabilità interindividuale dell'efficacia delle tiopurine sarà convalidata clinicamente nelle VE isolate dal plasma di pazienti pediatrici affetti da IBD trattati con tiopurine.

Vescicole Extracellulari (VE): nuovi biomarcatori per la risposta alla terapia con farmaci immunosopressori in pazienti pediatrici / Norbedo, Alessia. - (2023 Oct 06).

Vescicole Extracellulari (VE): nuovi biomarcatori per la risposta alla terapia con farmaci immunosopressori in pazienti pediatrici.

NORBEDO, ALESSIA
2023-10-06

Abstract

Thiopurines, such as mercaptopurine (MP), are immunosuppressive agents, used in the treatment of acute lymphoblastic leukemia (ALL) and inflammatory bowel disease (IBD). Thiopurine methyltransferase (TPMT) is an enzyme involved in thiopurines metabolism with activity modulated by Protein Kinase C and Casein Kinase Substrate in Neurons 2 (PACSIN2). Moreover, the PACSIN2 Single Nucleotide Polymorphism (SNP) rs2413739 eQTL is associated with MP-related gastrointestinal toxicity in children with ALL and with azathioprine efficacy in IBD pediatric patients. PACSIN2 is involved in vesicular trafficking and interacts with Rac1, a GTPase regulating cytoskeletal organization, and a molecular target of thiopurines. PACSIN2 may affect the release and content of extracellular vesicles (EVs), which mediate cell communication and whose cargo modifies phenotypes of target cells. This study evaluates mechanisms associating PACSIN2 polymorphism with interindividual variability in efficacy of thiopurines, by considering effects of PACSIN2 modulation on MP cytotoxicity, biomechanical properties and the release and content of EVs. Effects of stable PACSIN2 knock-down (KD) were evaluated in intestinal LS180 cells. MTT cytotoxicity assay was used to verify MP-sensitivity in both cell lines, then biomechanical properties, Rac1 protein expression and its GTPase activity were investigated respectively by atomic force microscopy (AFM), Western Blot assay (WB) and G-LISA assay in untreated cells and after MP exposure for 24, 48 and 72 hours at IC20, IC50 and IC80. EVs, released by LS180 MOCK and KD were isolated by ultracentrifuge and characterized by nanoparticle tracking analysis (NTA), scanning electron microscopy (SEM), AFM and WB. Intracellular and EVs miRNA-sequencing was performed by Illumina Hi-seq 2000. EVs may alter drug cytotoxicity, therefore LS180 MOCK and KD cells were co-treated with MP and EVs. Statistical analysis was performed using t-test and ANOVA. LS180 PACSIN2 KD were more sensitive to MP than control cells (MOCK) (IC50 LS180 MOCK 3.23 µM; IC50 LS180 KD 2.18 µM). Rac1 protein concentration was higher in LS180 KD cells compared to LS180 MOCK (fold change KD vs MOCK 20.6; p = 0.0009). MP caused a concentration- and dose-dependent reduction of Rac1 protein expression, GTPase activity and stiffness in both cell lines. No differences were observed in terms of release of EVs between MOCK and KD cells (MOCK, 9.39 * 1010 ± 6.50 * 109 particles/mL vs KD 9.91 * 1010± 3.41 * 1010; p = 0.8). PACSIN2 KD altered intracellular and EVs expression of 6 and 23 miRNAs respectively. EV-KD reduced MP cytotoxicity (about 10%): LS180 KD cell lines became more resistent than LS180 MOCK cell line. Moreover, EV-KD reduced Rac1 protein expression in LS180 KD cells (MOCK CTRL: 14.0 ± 5.9; EVs-MOCK: 22.6 ± 5.0; EVs-KD: 51.72 ± 19.8; KD CTRL: 138.9 ± 67.1; EVs-MOCK: 103.4 ± 19.0; EVs-KD: 63.3 ± 23.9; p < 0.001). In conclusion, PACSIN2 KD increases MP cytotoxicity by modifying EVs miRNAs, which could modulate Rac1 protein expression. The association of candidate miRNAs with interindividual variability in the efficacy of thiopurines will be clinically validated in EVs isolated from plasma of IBD pediatric patients treated with thiopurines.
6-ott-2023
LUCAFÒ, MARIANNA
STOCCO, GABRIELE
35
2021/2022
Settore BIO/14 - Farmacologia
Università degli Studi di Trieste
File in questo prodotto:
File Dimensione Formato  
Tesi PhD Alessia Norbedo Final.pdf

Open Access dal 06/10/2024

Descrizione: Tesi PhD Alessia Norbedo Definitiva
Tipologia: Tesi di dottorato
Dimensione 19.02 MB
Formato Adobe PDF
19.02 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/3060339
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact